Table 1 Relationship of C1orf63 expression with clinicopathologic features and biomarkers. 182 patients with breast cancer were included and the correlations between C1orf63 expression and clinicopathologic features were analyzed using chi-square test
Clinicopathological features | C1orf63 expression | Chisq | P | |
|---|---|---|---|---|
Negative (≤4) n = 138 (%) | Positive (>4) n = 44 (%) | |||
Age, year | Â | Â | Â | Â |
  ≤ 60 | 114 (74.5) | 39 (25.5) | 0.905 | 0.341 |
  > 60 | 24 (82.8) | 5 (17.2) |  |  |
T (Primary tumor) | Â | Â | Â | Â |
 T0 ~ T2 | 81 (75.0) | 27 (25.0) | 0.183 | 0.669 |
 T3 ~ T4 | 56 (77.8) | 16 (22.2) |  |  |
N (Regional lymph nodes) | Â | Â | Â | Â |
 N0 ~ N1 | 73 (78.5) | 20 (21.5) | 0.601 | 0.438 |
 N3 ~ N4 | 64 (73.6) | 23 (26.4) |  |  |
TNM stage | Â | Â | Â | Â |
 I ~ II | 58 (78.4) | 16 (21.6) | 0.315 | 0.575 |
 III ~ IV | 80 (74.8) | 27 (25.2) |  |  |
ER | Â | Â | Â | Â |
 Negative | 55 (79.7) | 14 (20.3) | 1.115 | 0.291 |
 Positive | 80 (72.7) | 30 (27.3) |  |  |
PR | Â | Â | Â | Â |
 Negative | 85 (79.4) | 22 (20.6) | 2.319 | 0.128 |
 Positive | 50 (69.4) | 22 (30.6) |  |  |
HER-2 | Â | Â | Â | Â |
 Negative | 82 (75.9) | 26 (24.1) | 0.061 | 0.804 |
 Positive | 52 (74.3) | 18 (25.7) |  |  |